Russia – Healthcare, Regulatory and Reimbursement Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Russia pharmaceutical market was valued at $29.0 billion in 2020. The market will grow at a CAGR of more than 4% during the forecast period. The Russia medical devices market was valued at $11.4 billion in 2020 and is expected to grow at a CAGR of less than 1% by 2026. The Russian pharmaceutical market is one of the most significant markets in the Central and Eastern European (CEE) region.

The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets.

Russia pharmaceuticals market overview

Russia pharmaceuticals market overview

For more insights on this report, download a free report sample

Russia medical devices market overview

Russia medical devices market overview

For more insights on this report, download a free report sample

What are the market dynamics in the Russia pharmaceuticals market?

In 2021, Russia was ranked 70th globally on the Legatum Prosperity Index. This rank was driven by the country’s education, economic quality and infrastructure, and market access scores. In 2020, the Russian government approved a package of measures to ensure regular supplies of drugs and avoid shortages in the domestic market. The growth in the Russian healthcare market is attributed to reforms in regulatory guidelines, government initiatives to develop the domestic pharmaceutical market, and the growing elderly population.

Who are the major import and export partners of the Russia pharmaceuticals market?

The major import partners of Russia are Germany, the US, Italy, Switzerland, and Ireland. Germany accounts for the highest percentage in the import business. The major export partners of Russia are Kazakhstan, Ukraine, Belarus, Uzbekistan, and Kyrgyzstan. Among them, Kazakhstan covers the majority of the business.

What are the major sub-segments in the Russia pharmaceuticals market?

The major sub-segments in the Russia pharmaceuticals market are generics, biologics, biosimilars, and over the counter (OTC).

Russia pharmaceuticals market, by sub-segment

 Russia pharmaceuticals market, by sub-segment

For more sub-segment insights, download a free report sample

Who are the major players in the Russia pharmaceuticals market?

The major players in the Russia pharmaceuticals market are GlaxoSmithKline (GSK), Novartis, Pfizer, Sanofi, and Pharmstandard. 

GSK

It is a healthcare company that focuses on the development, manufacture, and commercialization of pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of respiratory diseases, cancer, cardiovascular diseases, HIV, infectious diseases, immuno-inflammation, and rare diseases.

Novartis

Novartis is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products, as well as eye care products. It provides drugs for the treatment of cancer and other diseases.

Pfizer

It is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for various conditions, consumer healthcare products, generics, and APIs.

Russia pharmaceuticals market, by major players

Russia pharmaceuticals market, by major players

To know more about major players, download a free report sample

What are the market dynamics in the medical devices market in Russia?

The Russian medical devices market is one of the most attractive and largest markets in the Central and Eastern Europe (CEA) region. The majority of the hospitals here are federally owned and operated, leveraging the Russian government as the primary buyer of medical technology. Although the local medical device manufacturing industry is very small, the Russian government prioritizes domestic products over imported devices while making purchasing decisions. The Russian healthcare system relies on imports. Most of the high technology and innovative products are imported from Europe and the US.

What are the major sub-segments in the medical devices market in Russia?

The major sub-segments in the medical devices market in Russia are hospital supplies, general surgery, orthopedic devices, cardiovascular devices, and anesthesia and respiratory devices. Hospital supplies accounts for the majority of the revenue in the market anesthesia and respiratory devices account for the smallest part of the revenue.

Russia medical devices market, by sub-segment

Russia medical devices market, by sub-segment

For more sub-segment insights, download a free report sample

Who are the major players in the medical devices market in Russia?

Some of the major players in the medical devices market in Russia are Roche Diagnostics, Abbott, Zimmer Biomet Holdings Inc, and Medtronic.

Roche Diagnostics

It offers novel diagnostic tests and systems for the early identification, targeted screening, assessment, and monitoring of diseases. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers, and pharmacists.

Abbott

It is a diversified health product company that manufactures and markets drugs, diagnostics, branded generics, vascular products, and nutritional products. The company’s products comprise specialized medicines, medical diagnostic instruments and tests, minimally invasive surgical devices, and products for veterinary care.

Zimmer Biomet Holdings Inc (Zimmer Biomet)

It is a medical devices company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, spine products, craniomaxillofacial and thoracic products, office-based technologies, dental implants, and related surgical products.

Russia medical devices market, by major players

Russia medical devices market, by major players

To know more about major players, download a free report sample

Market report scope (pharmaceuticals market)

Market size (Year – 2020) $29.0 billion
Growth rate CAGR of >4%
Forecast period 2020-2026
Major sub-segments Generics, Biologics, Biosimilars, and Over the Counter (OTC)
Major import partners Germany, the US, Italy, Switzerland, and Ireland
Major export partners Kazakhstan, Ukraine, Belarus, Uzbekistan, and Kyrgyzstan
Major players GlaxoSmithKline (GSK), Novartis, Pfizer, Sanofi, and Pharmstandard

Market report scope (medical devices)

Market size (Year – 2020) $11.4 billion
Growth rate CAGR of <1%
Forecast period 2020-2026
Major sub-segments Hospital Supplies, General Surgery, Orthopedic Devices, Cardiovascular Devices, and Anesthesia and Respiratory Devices
Major players Roche Diagnostics, Abbott, Zimmer Biomet Holdings Inc, and Medtronic

This report provides:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: GSK, Sanofi, Pfizer, Novartis, and Pharmstandard.
  • Profiles and SWOT analyses of the major players in the medical device market: Roche, Abbott, Zimmer, and Medtronic.
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices.
  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure.
  • An overview of the opportunities for and challenges to growth in the Russian healthcare market.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the Russian healthcare market.
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact Russian healthcare market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance.
  • Organize sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership.

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts about the Russia Healthcare Market

2.3 Key Highlights: Healthcare Start-ups in Russia

2.4 Key Events: Healthcare Industry, Russia, 2015–2021

2.5 Key Events: Russia Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–2021

2.7 Key Events: Top Completed Deals by Value, 2020–2021

2.8 Country Profile, Russia, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Russia

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, Russia

3.7 COVID-19 Epidemiology, Russia

3.8 COVID-19 Impact and Developments, Russia

3.9 COVID-19 Impact and Developments in the Healthcare Market, Russia

3.10 COVID–19 Clinical Trials Landscape, Russia

3.11 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Russia, 2020–2021

6.2 Deal Analysis: Medical Device Market, Russia, 2020–2021

7. HealthTech Landscape

7.1 HealthTech Landscape, Russia

7.2 HealthTech Deals Landscape, Russia

7.3 Key HealthTech Deals, Russia

7.4 Adoption of Technology in Healthcare, Russia

7.5 Digital Health Regulations, Russia

7.6 HealthTech Landscape – Benefits and Risks, Russia

8. Market Access

8.1 Overview of Healthcare System, Russia

8.2 Reimbursement Process, Russia

8.3 Overview of Insurance Providers, Russia

8.4 Out-of-Pocket Spending and Consumer Price Index, Russia

8.5 Pricing Policies, Russia

8.6 Regulatory Landscape, Russia

8.6.1 Overview of Regulatory Agencies, Russia

8.6.2 Marketing Authorization for Pharmaceutical Products, Russia

8.6.3 Marketing Authorization for Medical Devices, Russia

8.6.4 Regulatory Reforms, Russia

8.6.5 Pharmaceutical Exports and Imports, Russia

8.6.6 Intellectual Property Rights, Patent, Russia

8.6.7 Clinical Trial Regulations, Russia

8.6.8 Pharmaceutical Clinical Trials Landscape, Russia

8.6.9 Medical Devices Clinical Trials Landscape, Russia

8.6.10 Pharmaceutical and Medical Device Advertising Regulations, Russia

8.6.11 Labeling and Packaging Regulations, Russia

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights, Russia

9.2 Healthcare Facilities, Russia

9.3 Healthcare Parameters, Russia

9.4 Life Expectancy and Immunization Rate, Russia

9.5 Environmental Health, Russia

9.6 Healthcare Personnel, Russia

9.7 Disease Burden, Russia

9.8 Healthcare Expenditure, Russia

10 Trade Associations, Russia

11 Trade Fairs, Russia

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Major Pharmaceutical Distributors, Russia, Q1- Q3 2021

Table 2: Sales Structure of “Temporary Recommendations for Use” (RTU drugs) by ATC groups, Russia, 2018

Table 3: COVID-19 Indicators (Number of Cases), Russia and Global, 2021

Table 4: COVID-19-Related Travel Restrictions, Russia, 2020–2021

Table 5: Available COVID-19 IVD products, Russia, 2020–2021

Table 6: Medical Devices Market, Russia, Major Segments ($B), 2020

Table 7: Hospital Supplies Market, Russia, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 8: General Surgery Devices Market, Russia, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 9: Orthopedic Devices Market, Russia, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 10: Cardiovascular Devices Market, Russia, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 11: Anesthesia and Respiratory Devices Market, Russia, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 12: Medical Equipment Risk Classification, Russia, 2020

Table 13: Patent Fees, Russia, 2020

Table 14: Trade Fairs, Russia

Figures

Figure 1: Pharmaceutical Market, Russia, Revenue ($B and RUB B), 2015–2020

Figure 2: Medical Device Market, Russia, Revenue ($B), 2016–2021

Figure 3: Healthcare Start-Ups in Russia, 2020

Figure 4: Country Profile, Russia, 2020

Figure 5: Pharmaceutical Market, Russia, Revenue ($B and RUB B), 2015–2020

Figure 6: Pharmaceutical Market, Russia, Revenue Forecast ($B and RUB B), 2021–2026

Figure 7: Pharmaceutical Exports ($B), Russia, 2011–2020

Figure 8: Top Export Partners, Russia, 2020

Figure 9: Pharmaceutical Imports ($B), Russia, 2011–2020

Figure 10: Top Import Partners, Russia, 2020

Figure 11: Russian Pilot Innovative Clusters Specialized in Pharmaceuticals and Medical Device, Russia, 2019

Figure 12: OTC Market, Revenue ($B), Russia, 2011–2020

Figure 13: OTC Medicines Market, Major Distribution Channels ($M), Russia, 2020

Figure 14: OTC Medicines Market, Major Market Value Segmentation (%), Russia, 2020

Figure 15: Major Therapeutic Categories Based on Mortality by Major Disease Areas (Thousands), Russia, 2019

Figure 16: COVID-19 (Number of Cases), Russia, 2020–2021

Figure 17: COVID-19 (Number of Deaths), Russia, 2020–2021

Figure 18: COVID-19 Fiscal and Monetary Stimulus Timeline, Russia, 2020–2021

Figure 19: COVID-19 Vaccine Administration, Number of Administered Doses, Russia, 2020–2021

Figure 20: Top COVID-19 Markets by Product Categories (Number of available marketed products), Russia, 2020–2021

Figure 21: Top COVID-19 IVD Products by Device Class (Number of available marketed products), Russia, 2020–2021

Figure 22: COVID-19 Clinical Trials Sponsors by Count, Russia, 2020–2021

Figure 23: COVID-19 Clinical Trials Count by Phase, Russia, 2020–2021

Figure 24: COVID-19 Clinical Trials Count by Trial Status, Russia, 2020–2021

Figure 25: Medical Devices Market, Russia, Revenue ($B), 2016–2021

Figure 26: Medical Devices Market, Russia, Revenue Forecast ($B), 2022–2026

Figure 27: Medical Devices Market, Russia, Major Segments (%), 2020

Figure 28: Hospital Supplies Market, Russia, Revenue ($B), 2017–2025

Figure 29: Hospital Supplies Market, Russia, Market Share of Major Players (%), 2020

Figure 30: General Surgery Devices Market, Russia, Revenue ($B), 2017-2025

Figure 31: General Surgery Devices Market, Russia, Market Share of Major Players (%), 2020

Figure 32: Orthopedic Devices Market, Russia, Revenue ($B), 2017–2025

Figure 33: Orthopedic Devices Market, Russia, Market Share of Major Players (%), 2020

Figure 34: Cardiovascular Devices Market, Russia, Revenue ($B), 2017–2025

Figure 35: Cardiovascular Devices Market, Russia, Market Share of Major Players (%), 2020

Figure 36: Anesthesia and Respiratory Devices Market, Russia, Revenue ($B), 2017–2025

Figure 37: Anesthesia and Respiratory Devices Market, Russia, Market Share of Major Players (%), 2020

Figure 38: Diagnostic Market, Russia, Revenue ($B), 2016–2021

Figure 39: Diagnostic Market, Russia, Revenue ($B), 2022–2026

Figure 40: Medical Devices Market, Russia, Revenue ($M) of Major Companies, 2020

Figure 41: Deal Value and Deal Count, Pharmaceutical Market, Russia, 2020–2021

Figure 42: Deal Value and Deal Count Subtypes, Pharmaceutical Market, Russia, 2020–2021

Figure 43: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, Russia, 2020–2021

Figure 44: Top Therapy Areas by Deal Value ($M), Pharmaceutical Market, Russia, 2020–2021

Figure 45: Top Therapy Areas by Deal Count, Pharmaceutical Market, Russia, 2020–2021

Figure 46: M&A Deals by Quarter, Pharmaceutical Market, Russia, 2020–2021 (by value and by number)

Figure 47: Deal Value and Deal Count, Medical Devices Market, Russia, 2020–2021

Figure 48: Deal Value and Deal Count Subtypes, Medical Devices Market, Russia, 2020–2021

Figure 49: Deal Value and Deal Count, Quarterly, Medical Devices Market, Russia, 2020–2021

Figure 50: Top Equipment Sectors by Deal Value ($M), Medical Devices Market, Russia, 2020–2021

Figure 51: Top Equipment Sectors by Deal Count, Medical Devices Market, Russia, 2020–2021

Figure 52: M&A Deals by Quarter, Medical Devices Market, Russia, 2020–2021 (by value and by number)

Figure 53: Deal Value and Deal Count, HealthTech, Russia, 2020–2021

Figure 54: Top VC Investors by Deal Value and Deal Count, HealthTech, Russia, 2020–2021

Figure 55: Organization of Healthcare System, Russia, 2020

Figure 56: Out-Patient Drug Reimbursement Eligibility, Russia, 2019

Figure 57: Public Provision of Pharmaceuticals, Russia, 2020

Figure 58: Government Health Insurance (% of population), Russia, 2010–2018

Figure 59: Out-of-Pocket Spending ($ per Capita), Russia, 2012–2019

Figure 60: Consumer Price Index, Health (2015=100), Russia, 2016–2020

Figure 61: Drug Price Regulation, Russia, 2020

Figure 62: Filing Procedure for Registration of Maximum Selling Price for EDL Drugs, Russia, 2020

Figure 63: Roszdravnadzor, Organizational Chart, Russia, 2020

Figure 64: Rospotrebnadzor, Organizational Chart, Russia, 2020

Figure 65: Drug Approval Process, Russia, 2020

Figure 66: Drug Approval Overall Process, Russia, 2020

Figure 67: Rospatent Organization Structure, Russia, 2020

Figure 68: Patent Approval Process, Russia, 2020

Figure 69: Pharmaceutical Clinical Trials Count by Trial Status, Russia, 2020–2021

Figure 70: Pharmaceutical Clinical Trials Count by Indication, Russia, 2020–2021

Figure 71: Pharmaceutical Clinical Trials Count by Phase, Russia, 2020–2021

Figure 72: Pharmaceutical Clinical Trials Count by Sponsors, Russia, 2020–2021

Figure 73: Medical Devices Clinical Trials Count by Trial Status, Russia, 2020–2021

Figure 74: Medical Devices Clinical Trials Count by Device Category, Russia, 2020–2021

Figure 75: Medical Devices Clinical Trials Count by Indication, Russia, 2020–2021

Figure 76: Top Five Medical Devices Clinical Trials Sponsors by Count, Russia, 2020–2021

Figure 77: Labeling information, Russia, 2020

Figure 78: Health Strategy 2020, Russia, 2020

Figure 79: Number of Hospitals & Outpatient Clinics (‘000), Russia, 2013–2020

Figure 80: Number of Diagnostic Equipment Units (per 100,000 population), Russia, 2013–2020

Figure 81: Number of Hospital Beds* (per 1,000 Population), Russia, 2011–2019

Figure 82: Number of Hospital Beds by Specialization (%), Russia, 2019

Figure 83: Life Expectancy at Birth (Years), Russia, 2013–2020

Figure 84: Immunization Rate (% of Children Ages 12–23 months), Russia, 2013–2020

Figure 85: PM2.5 (µg per m3), Russia, 2012–2020

Figure 86: CO2 Emissions (Mt of CO2 ), Russia, 2012–2020

Figure 87: Physicians (per 10,000 Population), Russia, 2013–2020

Figure 88: Nurses (per 10,000 Population), Russia, 2010–2020

Figure 89: Dentists (per 1,000 Population), Russia, 2010–2020

Figure 90: Major Causes of Mortality (per 100,000 population), Russia, 2019

Figure 91: Major Causes of Male Mortality (per 100,000 population), Russia, 2019

Figure 92: Major Causes of Female Mortality (per 100,000 population), Russia, 2019

Figure 93: Disability-Adjusted Life Years by Major Disease (per 100,000 population), Russia, 2019

Figure 94: Healthcare Expenditure as Percentage of GDP (%), Russia, 2012–2020

Figure 95: Health Expenditure Share (% of Health Spending), Russia, 2012–2019

Frequently asked questions

Russia – Healthcare, Regulatory and Reimbursement Landscape thematic reports
Currency USD
$1,995

Can be used by individual purchaser only

$5,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Russia – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Russia – Healthcare, Regulatory and Reimbursement Landscape in real time.

  • Access a live Russia – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.